Analysis of Databases from Health Care Systems or Large Epidemiologic Studies to Evaluate Safety of Testosterone Administration in Older Men (R01)

Post Date

July 28th 2011

Application Due Date

November 2nd 2011

Funding Opportunity Number

RFA-AG-12-007

CFDA Number(s)

93.866

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Funding

• Estimated Total Funding:

  $650000

• Award Range:

  $None - $150000

Grant Description

This FOA solicits R01 projects that aim to evaluate the safety of testosterone administration in older men by assessing the relationship of testosterone administration to adverse outcomes in clinical practice. Applicants are encouraged to submit applications to conduct analyses of databases from health care systems or epidemiologic studies that contain information on diagnoses, therapies, and testosterone levels. Additional information on safety of testosterone administration is needed because, although several small short-term clinical trials have been conducted in older men, these studies do not provide adequate information to assess the safety of testosterone as used in clinical practice. This information is important for clinicians and their older patients in decisions regarding starting or continuing testosterone therapy. Moreover, adequate information on safety is lacking in regard to many important adverse outcomes, particularly in regard to long-term testosterone use.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-12-007.html